ALLIANCE FOR CANCER GENE THERAPY I… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2001

Legal Domicile

Principal Officer

KEVIN HONEYCUTT

Phone

2033585055

Tax Period

2024-05-01 to 2025-04-30

ALLIANCE FOR CANCER GENE THERAPY INC, founded in 2001, is a community nonprofit in the Philanthropy & Grantmaking sector that reported $3.1M in total revenue in fiscal year 2024. Revenue fell 66% from the prior year — a significant decline worth monitoring. Expenses of $5.4M exceeded revenue, resulting in a 73% operating deficit.

Mission

ACGT SUPPORTS HIGH-RISK, HIGH-REWARD SCIENTIFIC RESEARCH TO DEVELOP CANCER THERAPEUTICS THAT USE THE BODY'S OWN CELLS AND GENES AS A LIVING MEDICINE. BY ACCELERATING THIS RESEARCH, ACGT IS HELPING TO ADVANCE THERAPIES THAT ARE SIGNIFICANTLY MORE EFFECTIVE AND LESS TOXIC THAN CURRENT CANCER TREATMENTS SUCH AS CHEMOTHERAPY AND RADIATION.

Program Service Accomplishments

Program 1

Expenses: $4,933,585 Revenue: $284,595

IN FISCAL 4/30/25, ACGT FUNDED CLINICAL INVESTIGATOR GRANTS AWARDED TO INNOVATIVE SCIENTISTS CONDUCTING TRANSLATIONAL RESEARCH AT PREMIER ACADEMIC INSTITUTIONS IN THE U.S., EACH FOCUSING ON THE...

IN FISCAL 4/30/25, ACGT FUNDED CLINICAL INVESTIGATOR GRANTS AWARDED TO INNOVATIVE SCIENTISTS CONDUCTING TRANSLATIONAL RESEARCH AT PREMIER ACADEMIC INSTITUTIONS IN THE U.S., EACH FOCUSING ON THE DEVELOPMENT OF CANCER CELL AND GENE THERAPIES FOR DIFFERENT CANCERS, INCLUDING PANCREATIC, PEDIATRIC, AND BRAIN CANCERS, AND CANCER METASTASIS. ACGT CONTINUED MULTI-YEAR COLLABORATIONS WITH MULTI-DISCIPLINARY 501(C)(3) ORGANIZATIONS FOCUSED ON CELL AND GENE THERAPY RESEARCH. ACGT FURTHER CONVENED ITS ANNUAL SCIENTIFIC SUMMIT AND ALSO INCREASED PUBLIC AWARENESS OF CELL AND GENE THERAPY RESEARCH THROUGH ACGT'S WEBSITE, SOCIAL MEDIA, AND IMPACT REPORTS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $1,933,872

Program Service Revenue $98,042

Investment Income $917,192

Other Revenue $154,414

TOTAL REVENUE $3,103,520

Expense Breakdown

Grants Paid $4,328,750

Salaries & Benefits $581,564

Fundraising Expenses $356,823

Program Expenses $4,933,585

Other Expenses $445,232

TOTAL EXPENSES $5,355,546

Year-over-Year Comparison

	2024	2023	Change
Revenue	$3,103,520	$9,059,178	-0.7%
Expenses	$5,355,546	$1,966,202	+1.7%
Net Income	$-2,252,026	$7,092,976	-1.3%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$273,222

Total Directors

Key Employees

$223,382

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
KEVIN HONEYCUTT	CEO & PRESIDENT	40.00	Officer Director	$0	$0	$0
MARC ENGELSGJERD MD	DIRECTOR (EFF 12/5/24)	1.00	Director	$0	$0	$0
DANIEL ENGLANDER	DIRECTOR	1.00	Director	$0	$0	$0
MARIA FARDIS PHD	DIRECTOR	1.00	Director	$0	$0	$0
PETER A GLICKLICH ESQ	DIRECTOR	1.00	Director	$0	$0	$0
MICHAEL GREGORY	DIRECTOR	1.00	Director	$0	$0	$0
CHAU Q KHUONG	DIRECTOR	1.00	Director	$0	$0	$0
JOHN LAHEY PHD	DIRECTOR	1.00	Director	$0	$0	$0
ALEXANDRA LANDES	DIRECTOR	1.00	Director	$0	$0	$0
BRUCE L LEVINE PHD	DIRECTOR	1.00	Director	$0	$0	$0
BARBARA NETTER	DIRECTOR, HONORARY CHAIRMAN	6.00	Director	$0	$0	$0
CHEN SCHOR	DIRECTOR	1.00	Director	$0	$0	$0
JOHN C SITES JR	DIRECTOR	1.00	Director	$0	$0	$0
KLAUS R VEITINGER MD PHD	DIRECTOR	1.00	Director	$0	$0	$0
MARTIN E WINTER	DIRECTOR	1.00	Director	$0	$0	$0
GBOLA AMUSA	DIRECTOR (THRU 6/27/24)	1.00	Director	$0	$0	$0
THERESA BURGESS PHD	DIRECTOR (THRU 6/27/24)	1.00	Director	$0	$0	$0
H WILLIAM SMITH	VICE PRESIDENT, LEGAL & SECRETARY	2.00	Officer	$0	$0	$0
CHRISTINE HERMAN	VICE PRESIDENT, TREAS(THRU 5/31/25)	2.00	Officer	$0	$0	$0
BARBARA LAVERY	CHIEF PROGRAM OFFICER	40.00	Officer	$264,230	$8,992	$273,222
KERI EISENBERG	CHIEF PHILANTHROPY OFFICER	40.00	Key Emp	$215,301	$8,081	$223,382

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$3,103,520	$5,355,546	$15,733,028	$-2,252,026
2024	$9,059,178	$1,966,204	$15,042,870	$7,092,974
2023	$3,231,770	$2,498,579	$7,929,383	$733,191
2022	$3,295,905	$1,804,221	$7,018,537	$1,491,684
2021	$1,716,695	$2,586,563	$6,851,434	$-869,868

ALLIANCE FOR CANCER GENE THERAPY INC